Amelioration of collagen-induced arthritis by human recombinant soluble FcγRIIb
2008 (English)In: Clinical Immunology, ISSN 1521-6616, Vol. 127, no 2, 225-233 p.Article in journal (Refereed) Published
Immune complex (IC) binding to Fc gamma receptors (FcγRs) is central for inflammatory reactions seen in autoimmune diseases. Consequently, a therapeutic agent with a possibility to interfere with binding of pathogenic IC to FcγRs would be valuable in autoimmune disorders such as rheumatoid arthritis (RA). Here we have explored the therapeutic effect of a recombinant solublehuman FcγRIIb (sFcγRIIb) protein in collagen-induced arthritis (CIA). In vitro studies of the sFcγRIIb demonstrated binding to mouse IgG, suggesting that sFcγRIIb can absorb pathogenic IgG anticollagen type II (CII) IC in vivo. Hence, administration of sFcγRIIb significantly reduced CIA severity compared to control treated mice. The sFcγRIIb treated mice had significantly less IgG anti-CII antibodies in serum and lowermRNA levels of inflammatory cytokines compared to controlmice. In conclusion, sFcγRIIb treatment ameliorates CIA by reducing IC-stimulated inflammation and joint swelling. This suggests that recombinant sFcγRIIb may be useful as therapeutic agent in RA.
Place, publisher, year, edition, pages
2008. Vol. 127, no 2, 225-233 p.
Fc gamma receptors, Collagen-induced arthritis, Mice, Autoimmunity, Therapy, Antibody, Rheumatology, Cytokines
Medical and Health Sciences
Research subject Immunology
IdentifiersURN: urn:nbn:se:uu:diva-98880DOI: 10.1016/j.clim.2008.02.002ISI: 000255231100015PubMedID: 18346938OAI: oai:DiVA.org:uu-98880DiVA: diva2:201459